[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346675-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346675-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","erythropoietin-drug-targets-and-cancer-risk-a-two-sample-mendelian-randomization-study","Erythropoietin Drug Targets and Cancer Risk - A Two-Sample Mendelian Randomization Study","","Erythropoiesis-stimulating agents (ESAs) are widely used to treat anemia, yet their on-target effects on tumor risk via erythropoietin (EPO)/erythropoietin receptor (EPOR) signaling remain disputed. This study assesses the potential causal relationship between EPO signaling and the risk of 14 site-specific cancers using a drug-target Mendelian randomization (MR) framework. EPOR cis-expression instruments were combined with FinnGen summary associations for cancer outcomes. Inverse variance weighting was the primary method, supported by MR-Egger and multiple sensitivity approaches. Genetically proxied EPO exposure increased prostate cancer risk (OR 1.07, 95% CI 1.02-1.12, P=3.30×10-3) and showed a suggestive bladder cancer association (OR 1.12, 95% CI 1.03-1.21, P=6.34×10-3) without robust multiple-testing confirmation. Sensitivity analyses indicated no substantial heterogeneity or horizontal pleiotropy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/erythropoietin-drug-targets-and-cancer-risk-a-two-sample-mendelian-randomization-study/346675/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/erythropoietin-drug-targets-and-cancer-risk-a-two-sample-mendelian-randomization-study/346675.png","ImageObject",300,407,{"name":42,"@type":43},"Emma Wilson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the study’s main goal regarding erythropoietin signaling and cancer?","Question",{"text":63,"@type":64},"To evaluate whether erythropoietin (EPO) signaling has a causal relationship with the risk of 14 site-specific cancers using a drug-target Mendelian randomization approach.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the researchers proxy EPO signaling in the Mendelian randomization analysis?",{"text":68,"@type":64},"They proxied EPO signaling using genetic instruments for the EPOR derived from cis-expression quantitative trait locus data from the eQTLGen Consortium.",{"name":70,"@type":61,"acceptedAnswer":71},"Which cancer types showed evidence of association, and how strong was it?",{"text":72,"@type":64},"Genetically proxied EPO exposure significantly increased prostate cancer risk, and it showed a suggestive association for bladder cancer that did not survive strict multiple-comparison correction; no significant associations were found for the other 12 cancers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346675,1790184161,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","®  \n Observational Study   \nErythropoietin drug targets and cancer risk A two-sample Mendelian randomization study  \nHailing Chen, PhDa , Xuefei Yang, MSa , Ting Huang, PhDa , Heran Zhou, MSa ,*  \n\n| Abstract\u003Cbr>Erythropoiesis-stimulating agents (ESAs) are widely used to treat anemia, but their on-target effects on tumor risk via erythropoietin (EPO)/erythropoietin receptor (EPOR) signaling remain debated. This study aims to evaluate the potential causal relationship between EPO signaling and the risk of 14 site-specific cancers using a drug-target Mendelian randomization (MR) approach. We proxied EPO signaling using genetic instruments for the EPOR, derived from cis-expression quantitative trait locus data from theeQTLGen Consortium. Summary-level genetic associations for 14 cancer types were sourced from the FinnGen consortium (R12 release) . We applied the inverse variance weighted method as the primary analysis, supplemented by MR-Egger, weighted median, weighted mode, and simple mode approaches. Sensitivity analyses, including Cochran Q test and pleiotropy-robust methods, were conducted to assess heterogeneity and validate result reliability. Overall, genetically proxied EPO exposure was significantly associated with an increased risk of prostate cancer (odds ratio: 1.07, 95% confidence interval: 1.02–1. 12, P = 3.30 × 10‐3), and this association remained statistically significant after multiple testing correction. A suggestive association was also observed for bladder cancer (odds ratio: 1. 12, 95% confidence interval: 1.03–1.21, P = 6.34 × 10‐3), though it did not survive strict correction for multiple comparisons. No significant associations were detected for the other 12 cancer types. Sensitivity analyses revealed no substantial heterogeneity or horizontal pleiotropy, supporting the robustness of the primary findings. This MR study provides novel genetic evidence supporting a potential causal role of EPO/EPOR signaling in prostate carcinogenesis, with a suggestive signal for bladder cancer. These findings highlight the importance of further investigating the tissue-specific oncogenic roles of EPO and underscore the need for cautious interpretation regarding the long-term safety of ESAs. In particular, the observed association with prostate cancer suggests that patients receiving ESAs for anemia management may warrant urological monitoring, although further validation is required. Future large-scale prospective studies and mechanistic investigations are warranted to validate these results and clarify their clinical relevance. |\n| --- |\n| Abbreviations: 95% CI = 95% confidence interval , cis-eQTL = cis-expression quantitative trait locus, EPO = erythropoietin, EPOR = erythropoietin receptor, ESAs = erythropoiesis-stimulating agents, IVs = instrumental variables, IVW = inverse variance weighted, MR = Mendelian randomization, OR = odds ratio, SNPs = single-nucleotide polymorphisms. |\n| Keywords: cancer, drug target, erythropoietin, Mendelian randomization |\n\n1. Introduction  \nCancer remains a leading cause of global morbidity and mortality, where even modest shifts in population-level risk can translate into substantial public health impact. [1] Erythropoiesisstimulating agents (ESAs), which act on the erythropoietin (EPO) pathway, are widely used to manage anemia in patients with chronic kidney disease or chemotherapy-induced cytopenia. [2] Despite their clinical utility, ESAs have been associated with safety concerns-including thromboembolic events and along-debated potential to influence tumor progression-leading  \nto boxed warnings, restricted indications, and dose-adjustment guidelines. [3,4] Establishing whether on-target modulation of EPO signaling causally affects cancer risk is therefore of direct relevance to drug development, regulatory oversight, and clinical practice.  \nMechanistically, EPO binds to its homodimeric receptor (erythropoietin receptor [EPOR]) and activates JAK2/STAT5 signaling, promoting surviva","cbCaibzsQ5WD7fNY","https://ap.wps.com/l/cbCaibzsQ5WD7fNY","pdf",1332476,"English","# Abstract\n# Introduction\n## Cancer risk context\n## ESA safety concerns and EPO/EPOR mechanism\n# Methods (implied from abstract)\n## Drug-target Mendelian randomization design\n## Statistical analyses and sensitivity checks\n# Results (implied from abstract)\n## Prostate cancer association\n## Bladder cancer suggestive signal\n## Non-significant findings for other cancers\n# Discussion (implied from abstract)\n## Clinical monitoring and interpretation of ESA safety\n# Conclusion (implied from abstract)\n## Need for further studies","[{\"question\":\"What is the study’s main goal regarding erythropoietin signaling and cancer?\",\"answer\":\"To evaluate whether erythropoietin (EPO) signaling has a causal relationship with the risk of 14 site-specific cancers using a drug-target Mendelian randomization approach.\"},{\"question\":\"How did the researchers proxy EPO signaling in the Mendelian randomization analysis?\",\"answer\":\"They proxied EPO signaling using genetic instruments for the EPOR derived from cis-expression quantitative trait locus data from the eQTLGen Consortium.\"},{\"question\":\"Which cancer types showed evidence of association, and how strong was it?\",\"answer\":\"Genetically proxied EPO exposure significantly increased prostate cancer risk, and it showed a suggestive association for bladder cancer that did not survive strict multiple-comparison correction; no significant associations were found for the other 12 cancers.\"}]","Erythropoietin Drug Targets and Cancer Risk - A Two-Sample Mendelian Randomization Study | PDF",1790062371,18,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc118af93748221aa7beaddf076cba1b.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b9225e5a7cb00c03132950f63358b48.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64565b4fc1927ebb34fbea776d65a977.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23613f088b14646c2f280393cf7d2720.webp",980,1306]